[HTML][HTML] Metalloproteinases and their inhibitors: potential for the development of new therapeutics

M Raeeszadeh-Sarmazdeh, LD Do, BG Hritz - Cells, 2020 - mdpi.com
The metalloproteinase (MP) family of zinc-dependent proteases, including matrix
metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs), and a disintegrin …

Cellular and molecular mechanisms of kidney fibrosis

S Djudjaj, P Boor - Molecular aspects of medicine, 2019 - Elsevier
Renal fibrosis is the final pathological process common to any ongoing, chronic kidney
injury or maladaptive repair. It is considered as the underlying pathological process of …

[HTML][HTML] Matrix metalloproteinases in renal diseases: a critical appraisal

O Zakiyanov, M Kalousová, T Zima… - Kidney and Blood Pressure …, 2019 - karger.com
Matrix metalloproteinases (MMPs) are endopeptidases within the metzincin protein family
that not only cleave extracellular matrix (ECM) components, but also process the non-ECM …

[HTML][HTML] A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma

AM Alchahin, S Mei, I Tsea, T Hirz, Y Kfoury… - Nature …, 2022 - nature.com
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults.
When ccRCC is localized to the kidney, surgical resection or ablation of the tumor is often …

[HTML][HTML] Transcriptional trajectories of human kidney injury progression

PE Cippà, B Sun, J Liu, L Chen, M Naesens… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. The molecular understanding of the progression from acute to chronic
organ injury is limited. Ischemia/reperfusion injury (IRI) triggered during kidney …

[HTML][HTML] Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis

H Yan, J Xu, Z Xu, B Yang, P Luo, Q He - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Renal fibrosis is a failed wound-healing process of the kidney tissue after chronic, sustained
injury, which is a common pathway and pathological marker of virtually every type of chronic …

New therapeutic targets in chronic kidney disease progression and renal fibrosis

S Rayego-Mateos, JM Valdivielso - Expert Opinion on Therapeutic …, 2020 - Taylor & Francis
Introduction The current therapeutic armamentarium to prevent chronic kidney disease
(CKD) progression is limited to the control of blood pressure and in diabetic patients, the …

Matrix metalloproteinase-7 and osteopontin serum levels as biomarkers for biliary atresia

B Aldeiri, T Si, Z Huang, N Torner, Y Ma… - Journal of pediatric …, 2023 - journals.lww.com
Objectives: Matrix metallopeptidase-7 (MMP-7) and osteopontin (OPN) are important
components in the pathophysiology of fibrosis in biliary atresia (BA). There has been much …

[HTML][HTML] Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease

E Petra, J Siwy, A Vlahou, J Jankowski - PLoS One, 2022 - journals.plos.org
Chronic kidney disease (CKD) is characterized by the loss of kidney function. The molecular
mechanisms underlying the development and progression of CKD are still not fully …

[HTML][HTML] Current concepts of biliary atresia and matrix metalloproteinase-7: a review of literature

M Nomden, L Beljaars, HJ Verkade… - Frontiers in …, 2020 - frontiersin.org
Biliary atresia (BA) is a rare cholangiopathy of infancy in which the bile ducts obliterate,
leading to profound cholestasis and liver fibrosis. BA is hypothesized to be caused by a viral …